| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,003 | 0,009 | 26.08. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| WESANA HEALTH Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 40,360 | 0,00 % | EQS-News: Fresenius SE & Co. KGaA: Fresenius verkauft 7,8 Millionen Fresenius Medical Care-Aktien im Wert von rund 300 Millionen Euro | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung
Fresenius verkauft 7,8 Millionen Fresenius Medical Care-Aktien im Wert von rund 300 Millionen... ► Artikel lesen | |
| ESSILORLUXOTTICA | 158,85 | -0,16 % | UV-Schutz reicht nicht mehr? Warum die nächste Generation von Brillengläsern für EssilorLuxottica, Alcon & Co. zum Technologiethema wird | ||
| SERNOVA BIOTHERAPEUTICS | 0,065 | -7,41 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 137,00 | +0,22 % | Align Technology Wins China Patent Case Against Angelalign | WASHINGTON (dpa-AFX) - Align Technology, Inc. (ALGN), said the Jinan Intermediate People's Court in China ruled in its favor in a patent infringement case against Angelalign Technology's Chinese... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,011 | -100,00 % | XFRA 79O: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNUGEN MEDICAL DEV.... ► Artikel lesen | |
| HEALWELL AI | 0,493 | +1,54 % | HEALWELL AI: HEALWELL AI's DARWEN AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation | Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN AI as a globally recognized... ► Artikel lesen | |
| INMODE | 12,875 | +0,47 % | InMode Ltd.: InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025 | YOKNEAM, Israel, Aug. 5, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,300 | 0,00 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| INVITAE | - | - | Patentstreit: Natera sichert sich 30 % Lizenzgebühr von Invitae | ||
| SPINEWAY | 0,118 | 0,00 % | Spineway: H1 2026 results | H1 2026 results Continued growth Stable resultsStrong embedded growth driversIssuance of straight bonds to finance future growth In thousands of eurosConsolidated financial statements - UnauditedH1... ► Artikel lesen | |
| ELEVANCE HEALTH | 346,30 | +0,26 % | Elevance Health Raises FY26 Guidance; Expects To Return To At Least 12% Adj. EPS Growth In 2027 | WASHINGTON (dpa-AFX) - Elevance Health (ELV) said second quarter results exceeded its outlook. The company increased 2026 EPS guidance to at least $20.10, and lifted 2026 adjusted EPS guidance... ► Artikel lesen | |
| MORE LIFE COMPANY | 0,038 | -4,01 % | XFRA 20MP: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMOUNTAIN VALLEY... ► Artikel lesen | |
| VERU | 2,800 | 0,00 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| CLOVER HEALTH INVESTMENTS | 3,570 | -2,19 % | CLOVER HEALTH INVESTMENTS, CORP. /DE - 8-K, Current Report | ||
| BONESUPPORT | 20,440 | -0,39 % | Bonesupport Holding AB: BONESUPPORT HOLDING AB (publ) - publishes Q2 2026 interim report | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2026.
"Strong growth and improved operating... ► Artikel lesen |